Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA

Cancer Gene Therapy

Volumn 6, Issue 3, 1999, Pages 263-270

  Wiehert, Anke ^a   Holm, Per Sonne ^a   Dietel, Manfred ^a   Lage, Hermann ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Atypical multidrug resistance; Gastric carcinoma; GPC3; MXR7; OCI 5

Indexed keywords

GLYPICAN; HEPARAN SULFATE; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; RIBOZYME; RNA; RZ967;

ARTICLE; CELL FREE SYSTEM; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; TIME;

BASE SEQUENCE; CELL-FREE SYSTEM; DRUG RESISTANCE, MULTIPLE; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PROTEOGLYCANS; RNA; RNA, CATALYTIC; TIME FACTORS;

EID: 0033129214     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700045     Document Type: Article

References (23)

1. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247.
2. Hughes-Benzie RM, Hunter AG, Allanson JE, Mackenzie AE. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet. 1992;43:428-435.
3. Hsu H-C, Cheng W, Lai P-J. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57:5179-5184.
4. Filmus J, Church JG, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol. 1988;8:4243-4249.
5. Lage H, Dietel M. Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5. Gene. 1997;188: 151-156.
6. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 1990;50:6100-6106.
7. Kellner U, Hutchinson L, Seidel A, et al. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer. 1997;71:817-824.
8. Lage H, Dietel M, Fröschle G, Reymann A. Expression of the novel mitoxantrone resistance-associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther. 1998;36:58-60.
9. Haseloff J, Gerlach W. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988; 334:585-591.
10. Koizumi M, Hayase Y, Iwai S, Kamiya H, Inoue H, Ohtsuka O. Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. 1989;17: 7059-7071.
11. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry. 1990;29:10695-10702.
12. Heidenreich O, Eckstein F. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J Biol Chem. 1992;267: 1904-1909.
13. Hendry P, McCall MJ, Santiago FS, Jennings PA. In vitro activity of minimized hammerhead ribozymes. Nucleic Acids Res. 1995;23:3922-3927.
14. Chomczynski P, Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
15. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA. 1991;88:10591-10595.
16. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995;55:2024-2028.
17. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol. 1996;106:275-280.
18. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett. 1993;31:71-74.
19. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer. 1994;70:239-243.
20. Ellis J, Rogers J. Design and specificity of hammerhead ribozymes against calretinin mRNA. Nucleic Acids Res. 1993;21:5171-5178.
21. Bertrand E, Pictet R, Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res. 1994;22:293-300.
22. Holm PS, Dietel M, Krupp G. Similar cleavage efficiencies of an oligonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene. 1995;167:221-225.
23. Hendry P, McCall MJ. A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes. Nucleic Acids Res. 1995;23:3928-3936.